(Q24250243)

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Anaemia in end-stage renal disease: pathophysiological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Anaemia in chronic renal disease: lessons learned since Seville 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Trials: the next 50 years. Large scale randomised evidence of moderate benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

The CREATE trial--building the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Anemia of renal failure. Use of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: description, findings, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

Reporting number needed to treat and absolute risk reduction in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Erythropoietin is approved for the treatment of anemia associated with renal failure, chemotherapy, preoperative anemia, and human immunodeficiency virus disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Quality of life in predialytic uremic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Development of the kidney disease quality of life (KDQOL) instrument.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Safety and efficacy of erythropoietin in children with chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Lessons from the Hemodialysis (HEMO) Study: an improved measure of the actual hemodialysis dose

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Trends in anemia at initiation of dialysis in the United States.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Quality of life in end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Normalization of hematocrit in hemodialysis patients does not affect silent ischemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

What are the short-term and long-term consequences of anaemia in CRF patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

How erythropoietin affects bone marrow of uremic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021

Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003967

7 January 2021